Back to results
US 12,161,711 B2Granted
Lassa virus vaccine
AssigneeCureVac AG
InventorsEdith Jasny, Benjamin Petsch
Life of this patent
Estimating the term…
Abstract
The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the Invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, (pharmaceutical) compositions or vaccines.
Claims14
A purified mRNA molecule comprising:
- a coding region encoding
- a Lassa virus Nucleoprotein (NP), said coding region comprising a RNA sequence at least about 95% identical to one of SEQ ID NOs:
- 937-1125, 1312-1500, 1687-1875, 2062-2250, 2437-2625, 2812-3000 or 3187-3375,
- wherein said mRNA comprises a 5′ cap, a heterologous 3′-UTR element and Poly-A sequence.
1 more element
Dependencies are inferred from the claim text.